J Gen Virol Try Microbiology Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Gen Virol 69 (1988), 1085-1090; DOI 10.1099/0022-1317-69-5-1085
© 1988 Society for General Microbiology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoon, J.-W.
Right arrow Articles by Kim, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoon, J.-W.
Right arrow Articles by Kim, M. K.
Agricola
Right arrow Articles by Yoon, J.-W.
Right arrow Articles by Kim, M. K.

Identification of Antigenic Differences Between the Diabetogenic and Non-diabetogenic Variants of Encephalomyocarditis Virus Using Monoclonal Antibodies

Ji-Won Yoon1, William Ko2, Yong-Soo Bae1, Chin Y. Pak1, Kazuhiko Amano1, Hyone-Myong Eun1 and Myung K. Kim1

1 Division of Virology, Department of Microbiology and Infectious Diseases and Laboratory of Viral and Immunopathogenesis of Diabetes, Julia McFarlane Diabetes Research Unit, The University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, Canada T2N 4N1
and2 Laboratory of Oral Medicine, NIDR, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

The M variant of encephalomyocarditis (EMC) virus consists of two biologically distinct variants: one, diabetogenic D variant (EMC-D) and the other, non-diabetogenic B variant (EMC-B). These two variants cannot be distinguished by hyperimmune sera. Monoclonal antibodies were generated against EMC-D or EMC-B to identify antigenic differences between these two variants. Fourteen independent hybrid cell lines, selected from seven separate fusions of mouse myeloma cells to spleen cells isolated from mice immunized with EMC-D, consisted of 12 hybrids which produced monoclonal antibodies that neutralized both EMC-D and EMC-B, and two hybrids (ED-HJ-23 and ED-HJ-31) which produced monoclonal antibodies that neutralized EMC-D but not EMC-B. Similarly, 16 independent hybrid cell lines, selected from eight separate fusions using spleen cells prepared from mice immunized with EMC-B, consisted of 15 hybrids which produced monoclonal antibodies neutralizing both EMC-D and EMC-B, and one hybrid (EB-48A-F1) which produced antibody that neutralized EMC-B, but not EMC-D. The specificities of these monoclonal antibodies (ED-HJ-23, ED-HJ-31, EB-48A-F1) were further confirmed using an immunofluorescent technique. The D variant-specific monoclonal antibodies reacted with cells infected with EMC-D but not EMC-B. In contrast, the B variant-specific monoclonal antibody reacted with the cells infected with EMC-B but not EMC-D. It is concluded that the EMC-D- and EMC-B-specific monoclonal antibodies are able to identify antigenic differences between diabetogenic and non-diabetogenic variants of EMC virus which cannot be distinguished by hyperimmune sera.

Keywords: EMC virus, antigenic differences, cardiovirus

Received 5 November 1987; accepted 22 February 1988.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1988 by the Society for General Microbiology.